Cat. #153621
Anti-Vitronectin V65 subunit [pAb-V65]
Cat. #: 153621
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 10-12 weeks
Target: Vitronectin V65 subunit
Class: Polyclonal
Application: ELISA ; WB
Reactivity: Human
Host: Rabbit
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Mohammed Sharif
Institute: University of Bristol
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-Vitronectin V65 subunit [pAb-V65]
- Alternate name: Complement S Protein antibody, Epibolin antibody, S Protein antibody, Serum Spreading Factor antibody, Somatomedin B antibody, Vitronectin V65 subunit antibody, VN antibody, VNT antibody, VTNC_HUMAN antibody
- Research fields: Immunology;Tissue-specific biology
- Clone: pAb-V65
- Tool sub type: Primary antibody
- Class: Polyclonal
- Purpose: Marker
- Conjugation: Unconjugated
- Reactivity: Human
- Host: Rabbit
- Application: ELISA ; WB
- Description: Osteoarthritis (OA) is the most common chronic joint disease usually diagnosed at relatively advanced stages when there is irreparable damage to the joint(s). Recently, two novel biomarkers C3f and V65 were identified which appear to be OA-specific and therefore potential markers of early disease. The polyclonal antibody Anti-Vitronectin V65 subunit [pAb-V65] was developed and validated for the measurement of V65 in patient serum.
- Immunogen: V65 peptide-carrier conjugate. The carrier protein is Keyhole Limpet Haemocyanin (KLH).
- Recommended controls: Synthetic peptide
Target Details
- Target: Vitronectin V65 subunit
- Tissue cell line specificity: Rabbit
- Target background: Osteoarthritis (OA) is the most common chronic joint disease usually diagnosed at relatively advanced stages when there is irreparable damage to the joint(s). Recently, two novel biomarkers C3f and V65 were identified which appear to be OA-specific and therefore potential markers of early disease. The polyclonal antibody Anti-Vitronectin V65 subunit [pAb-V65] was developed and validated for the measurement of V65 in patient serum.
Applications
- Application: ELISA ; WB
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS
- Storage conditions: -15° C to -25° C
- Shipping conditions: Shipping at 4° C
References
- Ourradi et al. 2017. PLoS One. 12(7):e0181334. PMID: 28715494.
- Development and validation of novel biomarker assays for osteoarthritis.